Delving into the Latest Updates on Liraglutide(Aulbio) with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

AUL002-D, AUL002-O

Target

GLP-1R

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus

Inactive Indication-

Originator Organization

Aulbio Co., Ltd.Startup

Active Organization

Aulbio Co., Ltd.Startup

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

An open label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose,cross-over, bioequivalence study of Liraglutide 0.6 mg Injection (6 mg/mL) (Test) of VirchowBiotech Private Limited, India and VictozaÂ® (Liraglutide) injection in pre-filled pen 0.6 mg (6 mg/mL) of Novo Nordisk A/S Novo AllÃ© DK-2880 BagsvÃ¦rd, Denmark in normal, healthy adult,human subjects under fasting conditions. - Nil

Start Date26 Dec 2022

Sponsor / Collaborator

Virchow Biotech Pvt Ltd.

CTRI/2020/07/026753

/ CompletedPhase 1

An open label, balanced, randomized, two treatment, two period, two-way crossover study to compare the single & multiple dose (steady state) pharmacokinetics profile of Biosimilar Liraglutide injection with VictozaÂ® in healthy adult, human subjects.

Start Date14 Jul 2020

Sponsor / Collaborator

Levim Biotech LLP

100 Clinical Results associated with Liraglutide(Aulbio)

Login to view more data

100 Translational Medicine associated with Liraglutide(Aulbio)

Login to view more data

100 Patents (Medical) associated with Liraglutide(Aulbio)

Login to view more data

100 Deals associated with Liraglutide(Aulbio)

Login to view more data